Overactive Bladder — Symptoms, Causes & Treatment | MyMedicPlus

Overactive bladder (OAB) is a lower urinary tract symptom syndrome defined by the International Continence Society (ICS) as the presence of urinary urgency — a sudden, compelling, difficult-to-defer desire to void — usually accompanied by urinary frequency (urinating 8 or more times in 24 hours) and nocturia (waking to urinate 2 or more times per night), with or without urgency urinary incontinence (UUI — involuntary leakage associated with urgency), in the absence of a urinary tract infection or other proven pathological process. OAB is one of the most prevalent chronic health conditions worldwide — affecting approximately 400 million people globally, approximately 1 in 6 adults, with prevalence increasing substantially with age (affecting 3% of adults aged 18-24 rising to 30-40% of adults over 75 years). It affects both men and women, though UUI (OAB wet) is more prevalent in women; in men, OAB symptoms are often associated with benign prostatic hyperplasia (BPH) causing bladder outlet obstruction. The underlying pathophysiology involves detrusor overactivity — abnormal involuntary contractions of the detrusor muscle (the smooth muscle of the bladder wall) during the filling phase, lowering the threshold for the micturition reflex and generating urgent voiding signals before the bladder is physiologically full. OAB causes profound impairment in quality of life — limiting daily activities, employment, social participation, sexual function, and sleep — often more disabling than many more recognised chronic conditions. Despite its prevalence and impact, OAB is significantly undertreated, with only 27% of affected people seeking medical help, largely due to embarrassment and a misconception that it is a normal part of ageing.

OAB is classified as idiopathic (no identifiable neurological or local pathological cause — the majority) or neurogenic (from neurological conditions affecting bladder control). The pathophysiology is multifactorial: detrusor muscle overactivity driven by afferent C-fibre sensitisation (bladder wall sensory nerve endings become hypersensitive, generating premature urgency signals); increased urothelial (bladder lining) ATP release, activating P2X3 purinergic receptors on submucosal sensory nerves; reduced central inhibitory control of the micturition reflex (from frontal lobe or pontine micturition centre dysfunction). Neurogenic OAB causes: stroke (bladder hyperreflexia from loss of frontal cortical inhibition of the detrusor — one of the most common post-stroke neurological complications, affecting 40-60%); Parkinson's disease (detrusor overactivity from dopaminergic pathway involvement — urinary urgency in 40-70%); multiple sclerosis (spinal cord and pontine lesions affecting micturition centre control); spinal cord injury (neurogenic detrusor overactivity from loss of supraspinal inhibition — in supra-sacral lesions above S2-4); and dementia. Local pelvic and bladder factors: benign prostatic hyperplasia (BPH) — bladder outlet obstruction causes compensatory detrusor hypertrophy and overactivity; bladder outlet obstruction from pelvic organ prolapse in women; interstitial cystitis/painful bladder syndrome; bladder stones or cancer (must be excluded in haematuria); recurrent UTI causing bladder sensitisation; atrophic vaginitis/urogenital atrophy (postmenopausal oestrogen deficiency sensitising the bladder and urethral trigone); and bladder wall thickening from chronic infection or inflammation. Risk factors: increasing age (age-related detrusor changes, reduced central inhibitory control, lower functional bladder capacity); female sex (shorter urethra, oestrogenic effects, higher UTI frequency); obesity (increased intra-abdominal pressure, increased OAB prevalence 30-40% compared to normal BMI); diabetes (autonomic neuropathy affecting detrusor muscle and afferent innervation); caffeine consumption (bladder irritant, diuretic effect); alcohol (diuretic); constipation (pelvic floor and pelvic nerve effects on bladder function); and bladder irritant foods (spicy food, citrus, carbonated drinks).

The ICS symptom complex of OAB comprises: urgency (the core symptom — a sudden, compelling urge to urinate that is difficult to defer, without equivalent warning to normal bladder filling sensation); urinary frequency (voiding 8 or more times per 24 hours — may be substantially more frequent in severe OAB, with patients voiding every 30-60 minutes); nocturia (waking to urinate 2 or more times per night — one of the most disabling symptoms of OAB, profoundly disrupting sleep quality, causing daytime fatigue, and increasing falls risk in the elderly from nocturnal mobilisation); and urgency urinary incontinence (UUI) — present in OAB wet (approximately 30-50% of OAB patients). UUI is involuntary leakage of urine associated with or immediately following urgency — ranging from a few drops to large volume leakage before reaching the toilet; precipitated by triggers (sound of running water, hand-washing, cold weather, entering the house, opening a front door, or simply anticipating voiding). Bladder diary (voiding diary): essential for objective assessment — patients record voiding times, volumes, fluid intake, urgency episodes, and incontinence episodes over 3 days; provides objective evidence of frequency, functional bladder capacity, urgency episodes, and fluid intake patterns. 'Latch-key urgency' (also called 'key-in-door urgency'): a classic OAB presentation — the patient urgently needs to void on approaching their home and inserting the key in the door — thought to be a conditioned Pavlovian response with the proximity to a toilet triggering detrusor urgency. Quality-of-life impact: OAB causes significant restriction of social activities, avoidance of environments without easy toilet access (aeroplanes, meetings, films, countryside), occupational impairment, sexual dysfunction, sleep disturbance, depression (40-50% prevalence in severe OAB), and social isolation.

OAB is primarily a clinical diagnosis based on the symptom complex, excluding identifiable local and neurological causes. Clinical assessment: detailed urinary symptom history including symptom duration, severity, precipitating triggers, fluid intake, and impact on quality of life; ICIQ-OAB (International Consultation on Incontinence Questionnaire — Overactive Bladder) and OAB-q questionnaires quantify symptom burden and quality-of-life impact; rectal examination to assess prostate size (men — BPH causing obstruction) and pelvic floor function; pelvic examination in women to assess pelvic organ prolapse and urogenital atrophy (pale, thin vaginal mucosa, loss of rugae, reduced elasticity from postmenopausal oestrogen deficiency); neurological assessment if neurogenic cause is suspected. Urinalysis and urine culture: mandatory first investigation to exclude urinary tract infection (UTI — the most common and treatable cause of urgency symptoms) and screen for haematuria (blood in urine — if present, urological investigation to exclude bladder cancer is required, even in OAB clinical presentations). Urine dipstick: proteinuria, nitrites, leukocytes. 3-day bladder diary: essential for OAB assessment — records voiding frequency (above 8/day), functional bladder capacity (below 250mL is characteristic of OAB), nocturnal voids, urgency episodes, UUI episodes, and fluid intake. Post-void residual (PVR) urine measurement by bladder ultrasound scan: elevated PVR (above 150mL) suggests impaired bladder emptying (detrusor underactivity, BPH obstruction) rather than pure OAB — important to identify as antimuscarinics may worsen urinary retention in those with incomplete bladder emptying. Urodynamic studies (cystometry): not required for initial OAB diagnosis but used before invasive treatment (botulinum toxin, sacral neuromodulation, augmentation cystoplasty); cystometrogram demonstrates detrusor overactivity (involuntary detrusor contractions above 15 cmH2O during filling phase with provocation) in 60-70% of OAB patients; urodynamics also assess bladder compliance, capacity, and sensation. Cystoscopy with bladder biopsy: performed when haematuria is present, OAB fails to respond to treatment (bladder cancer, interstitial cystitis, bladder stones), or there is clinical suspicion of bladder pathology.

OAB management follows a stepped approach from behavioural interventions through pharmacological to interventional therapies, with each step added or substituted based on response and tolerability. First-line: bladder training (the most effective initial treatment) — patients are instructed to progressively delay voiding beyond the first sensation of urgency, gradually increasing inter-void interval from their current frequency to every 3-4 hours over 6-12 weeks; urgency suppression techniques (the 'freeze and squeeze' technique: standing still, crossing legs, contracting pelvic floor muscles, and distracting attention until urgency subsides) are taught; bladder training achieves a 50-80% improvement in frequency, urgency, and UUI in 6-12 weeks of consistent practice. Fluid management: reducing excessive fluid intake (more than 2-3 litres/day) by approximately 25%, eliminating or reducing caffeine and alcohol, avoiding carbonated drinks and known bladder irritants. Pelvic floor muscle training (PFMT — Kegel exercises): supervised by a pelvic health physiotherapist, PFMT strengthens pelvic floor muscles that can reflexly suppress detrusor overactivity; recommended for all OAB patients, particularly those with mixed stress and urgency incontinence. Second-line pharmacotherapy (where conservative treatment is insufficient): antimuscarinics (anticholinergics) — block M2 and M3 muscarinic acetylcholine receptors on the detrusor, reducing involuntary contractions; tolterodine immediate-release (2mg BD) or extended-release (4mg once daily) — efficacy comparable to oxybutynin but better tolerated; solifenacin (5-10mg daily) — once daily, moderate efficacy; oxybutynin (5mg TDS or extended-release 5-20mg daily — higher anticholinergic side effects: dry mouth, constipation, blurred vision, cognitive effects in elderly — oxybutynin crosses the blood-brain barrier readily); trospium; darifenacin; fesoterodine; antimuscarinics are avoided in patients with urinary retention, narrow-angle glaucoma, and severe constipation; cognitive concerns limit their use in the elderly (increased dementia risk with prolonged use in some observational studies). Mirabegron (Betmiga — 50mg once daily, beta-3 adrenergic receptor agonist): relaxes detrusor smooth muscle by activating beta-3 receptors, increasing bladder storage capacity; comparable efficacy to antimuscarinics with superior tolerability (no anticholinergic side effects, fewer cognitive concerns); now first-line alternative to antimuscarinics, particularly in the elderly; contraindicated in severe uncontrolled hypertension. Combination mirabegron plus solifenacin superior to monotherapy (SYNERGY trial). Third-line interventional therapy: intradetrusor onabotulinumtoxinA injection (Botulinum toxin A, 100 units — NICE approved for idiopathic OAB): cystoscopically injected into the detrusor muscle at 20 sites; blocks acetylcholine release from motor nerve terminals, reducing involuntary contractions; achieves 60-70% response rate, median 6-9 month effect, requires repeat injection; risk of urinary retention (6-12% requiring clean intermittent self-catheterisation). Sacral neuromodulation (InterStim): implanted sacral nerve stimulator (S3 level) modulates afferent sensory pathways to the bladder and pelvic floor; 60-80% responder rate in refractory OAB; a staged procedure (trial stimulator before permanent implant). Percutaneous tibial nerve stimulation (PTNS — Urgent PC): office-based neuromodulation via a needle electrode at the ankle stimulating the tibial nerve (sharing sacral nerve roots with bladder innervation); 12 weekly sessions, then monthly maintenance; 60% response rate. Augmentation cystoplasty and urinary diversion: last resort for refractory severe neurogenic OAB.

Urge urinary incontinence (UUI) is the most distressing consequence of OAB — affecting 30-50% of OAB patients, causing involuntary large-volume urine leakage that profoundly impacts dignity, social participation, and daily functioning. Complications of urinary incontinence: perineal dermatitis (skin excoriation from constant urine contact — increased risk of pressure ulcers and secondary infection in elderly); falls and fractures — nocturia from OAB is a well-established falls risk factor, particularly in elderly women; nocturnal urgency causing rushed mobilisation in the dark contributes substantially to the 50,000 annual hip fracture deaths in the UK. Sleep disruption from nocturia: waking 2 or more times nightly causes significant non-restorative sleep, daytime fatigue, impaired cognitive function, reduced workplace performance, and increased cardiovascular and metabolic risk from chronic sleep deprivation. Psychological complications are profound and underappreciated: depression (affecting 40-50% of those with severe OAB), anxiety (fear and anticipation of urgency episodes), social isolation and withdrawal (avoiding travel, restaurants, social events, exercise), and sexual dysfunction (fear of incontinence during intercourse causes avoidance and relationship problems). Complications of OAB treatment: antimuscarinic drugs cause dry mouth (30-60%), constipation (which itself worsens OAB), blurred vision, urinary retention (2-5%), and cognitive impairment — particularly problematic in elderly patients (anticholinergic burden contributes to dementia risk); mirabegron occasionally raises blood pressure. Botulinum toxin injection causes temporary urinary retention requiring clean intermittent self-catheterisation (CISC) in 6-12% of patients — all patients must be counselled on and willing to perform CISC before proceeding with botulinum toxin.

Primary prevention of OAB is not always possible given that the dominant risk factors (age, sex, neurological disease) are not modifiable. However, addressing modifiable risk factors significantly reduces OAB risk and severity. Weight management: achieving a healthy BMI (18.5-25) is one of the most effective preventive and therapeutic measures — obesity substantially increases OAB risk and severity; the PRIDE trial demonstrated that a 5-10% body weight reduction achieved a significant reduction in urge incontinence episodes in obese women. Fluid and dietary modification: maintain adequate but not excessive fluid intake (1.5-2 litres/day); reduce caffeine (tea, coffee, energy drinks, cola) by gradually substituting decaffeinated alternatives — caffeine reduction is associated with a 25% reduction in urgency episodes; reduce alcohol and carbonated drinks; avoid constipation (high-fibre diet, adequate fluid — constipation worsens OAB through pelvic floor and nervous system mechanisms). Pelvic floor exercises: regular pelvic floor muscle training initiated before pelvic surgery (hysterectomy, prostatectomy) and sustained regularly in mid-life substantially reduces later incontinence risk. Prompt treatment of urinary tract infections prevents repeated bladder sensitisation and potential progression to chronic OAB. Postmenopausal women should be informed about the role of topical vaginal oestrogen (cream, pessary, or vaginal ring) in reducing urogenital atrophy — a treatable and reversible contributor to OAB symptoms in postmenopausal women; systemic absorption is negligible, making it safe even in women with contraindications to systemic HRT. Smoking cessation: smoking is a risk factor for OAB through multiple mechanisms (chronic cough causing urethral trauma, direct bladder irritant effects of nicotine metabolites).

See your GP for: urinary urgency occurring more than 8 times daily significantly impacting your daily life, sleep, or social activities (OAB — highly treatable with behavioural therapy and medication); urge incontinence (involuntary leakage with urgency) — effective treatments are available and you should not feel embarrassed or accept this as normal; nocturia waking you 2 or more times per night (OAB is a treatable cause of nocturia, alongside heart failure, diabetes insipidus, and sleep apnoea — all of which should be excluded). Seek urgent assessment for: blood in urine (haematuria — visible blood or blood on urine dipstick must be urgently investigated to exclude bladder cancer even in patients with known OAB symptoms); inability to urinate despite urgency (acute urinary retention — requires emergency catheterisation); new onset of urgency symptoms with back pain, leg weakness, or saddle anaesthesia (cauda equina syndrome — spinal surgical emergency). OAB is underreported — many people manage symptoms by restricting fluids, limiting social activities, and using multiple pads daily without seeking help. Treatments including bladder training, pelvic floor physiotherapy, antimuscarinics, mirabegron, and botulinum toxin are highly effective and can achieve dramatic symptom improvement. Don't assume urinary urgency is an inevitable consequence of ageing — it isn't, and effective evidence-based treatments are available at all ages.